Objectives
Biosimilars are highly similar to an originator biologic, with no clinically meaningful differences in safety or efficacy. The adoption of biosimilars might provide an opportunity to lower costs and increase patient access to biologics. The current study sought to understand real-world implementation experiences associated with oncology MAbs biosimilars (trastuzumab, rituximab, and bevacizumab) from both payer and healthcare professional (HCP) perspectives.
Methods
In-depth qualitative telephone interviews with 20 each of US HCPs (including 3 practice managers) and payers were conducted. The HCPs were either affiliated with a healthcare network or were community-based. They specialized in hematology/oncology and had experience prescribing oncology biosimilars. Participating payers included Managed Care Organizations (MCOs), Integrated Delivery Networks (IDNs) and Pharmacy Benefit Managers (PBMs). Audio transcripts of the interviews were coded using MaxQDA software.
Results
Over 80% of HCPs interviewed perceived biosimilars to be highly comparable to originators in efficacy and safety. About 70% of HCPs reported using biosimilars in >50% of their treatment-naïve patients and were comfortable with use of biosimilars in all approved indications. To encourage utilization, approximately 75% of MCO/PBM payers preferred biosimilars over originators in treatment-naïve patients, which was implemented through step therapy. HCP involvement in choosing a biosimilar for their patients was minimal, and biosimilars were often automatically ordered by pharmacists or administrators based on practice protocols or patients’ cost due to insurance preferences. The major factor that influenced both payers’ coverage decisions and HCP adoption of biosimilars was potential cost savings. Moreover, payers considered HCPs’ clinical confidence with biosimilars as a factor influencing their biosimilar coverage decisions.
Conclusions
Both HCPs and payers in the US have favorable views of oncology MAbs biosimilars, particularly among treatment-naïve patients. A framework for biosimilars integration into oncology practice is developing, which is primarily driven by insurance coverage policy, contracting, and cost benefits.
Article info
Identification
Copyright
© 2021 Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
